Non-familial hypertrophic cardiomyopathy

Non-familial hypertrophic cardiomyopathy (HCM) is a form of hypertrophic cardiomyopathy that occurs sporadically, meaning it arises in individuals without a family history of the condition and without an identifiable inherited genetic mutation. Like all forms of HCM, it is characterized by abnormal thickening (hypertrophy) of the heart muscle, particularly the left ventricle and interventricular septum, in the absence of another cardiac or systemic condition that could explain the degree of hypertrophy. This thickening can impair the heart's ability to pump blood efficiently and may obstruct blood flow out of the left ventricle (left ventricular outflow tract obstruction). Key symptoms include exertional dyspnea (shortness of breath during physical activity), chest pain, palpitations, dizziness, syncope (fainting), and exercise intolerance. In some cases, the first presentation may be a life-threatening arrhythmia or sudden cardiac death, particularly in young individuals and athletes. The condition primarily affects the cardiovascular system, but symptoms can significantly impact overall functional capacity and quality of life. Diagnosis is typically made through echocardiography or cardiac MRI, which reveals the characteristic ventricular wall thickening, often defined as a wall thickness of 15 mm or greater in adults. Treatment of non-familial HCM follows the same principles as familial forms and is aimed at symptom management and prevention of complications. First-line pharmacological therapies include beta-blockers and calcium channel blockers (such as verapamil) to reduce heart rate and improve diastolic filling. The cardiac myosin inhibitor mavacamten has been approved for the treatment of symptomatic obstructive HCM. For patients with significant outflow tract obstruction refractory to medical therapy, septal reduction therapies such as surgical septal myectomy or alcohol septal ablation may be considered. Implantable cardioverter-defibrillators (ICDs) are recommended for patients at high risk of sudden cardiac death. Patients are generally advised to avoid strenuous competitive sports and to undergo regular cardiac monitoring.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Non-familial hypertrophic cardiomyopathy